Press enter to activate the dialog and use the tab key to navigate through the options.

Verve Therapeutics Company Logo
  1. Top Workplaces
  2. Verve Therapeutics

Verve Therapeutics

Verve Therapeutics is a clinical-stage genetic medicines company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company is pioneering a new approach to the care of cardiovascular disease, potentially transforming treatment from chronic management to single-course gene editing medicines. The company is advancing a pipeline of precision genetic medicines, and our initial three programs – VERVE-101, VERVE-102, and VERVE-201 – target genes that have been extensively validated as targets for lowering low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Our lead program, VERVE-101, designed to permanently turn off the PCSK9 gene in the liver, is currently being evaluated in the Phase 1b heart-1 clinical trial, enrolling patients with heterozygous familial hypercholesterolemia (HeFH), a potentially fatal genetic heart disease.... Read more

Purpose

At Verve, we are pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines.... Read more

Vision

Verve Therapeutics was created with a singular focus: to protect the world from cardiovascular disease.... Read more

Mission

We are striving to build the preeminent company developing gene editing medicines to treat patients with cardiovascular disease, leveraging the expertise and capabilities of our team whose singular focus is on addressing the root causes of the world’s most common cause of death. Our goal is to disrupt today’s chronic care model for treating cardiovascular disease by providing a new therapeutic approach with single-course gene editing treatments.

Verve brings together multiple breakthroughs in 21st century biomedicine — human genetic analysis, gene editing, messenger RNA (mRNA)-based therapies and lipid nanoparticle (LNP) delivery — to realize a new future of longevity and vitality for tens of millions of people around the globe with or at risk for cardiovascular disease.
... Read more

Additional Culture Details

At Verve, people are at the heart of everything that we do – from the patients with cardiovascular disease that we serve, to the employees dedicated to bringing these new treatment options forward. Verve has been purpose-built to deliver against our mission, and to do so, we have cultivated a connected and caring environment, rooted in teamwork and collaboration.

Our commitment to patients and each other starts at the top, with a leadership team that is transparent, communicative and supportive of culture-building activities. We recently introduced an internal “Ask Me Anything” series with the executive team, giving the opportunity for employees to directly engage with leadership and hear first-hand the latest decisions being made that affect the company, where no topic is off limits. We have established a vibrant cross-functional culture team, called the Heartbeat, that meets regularly to discuss how to best support our employees and foster an even more inclusive culture where talent and authenticity continue to be recognized and encouraged. The Heartbeat team has set up initiatives such as a fireside chat career development series, celebrating diversity through cuisine, building connection through team events, and creating opportunities to give back to the community. We also take advantage of our Fenway neighbors with team building opportunities at Red Sox games.
... Read more

Values

Verve Values
The name Verve comprises a spirit of enthusiasm, energy, and vitality—all of which are reflected in the values that we share: grit, spirit, drive and passion.

Headquarters

Boston, MA

Employees

232 US Employees

Industry

Biotechnology

Recent Awards

  • 2023

  • 2022

  • 2021

Company Snapshots

211006_Verve_Candids_Gallery(68)-9351.jpg
20220804_123536.jpg
20220721_130037.jpg
Thompson Island 2022.jpeg